Individuals carrying anti-citrullinated protein antibodies (ACPA) are considered at high risk of developing rheumatoid arthritis (RA). The altered expression of miRNAs contributes to the pathogenesis of RA. We aimed to identify differentially expressed miRNAs in the peripheral blood of ACPA-positive individuals with arthralgia at risk of RA compared to healthy controls (HC) and to determine their implications in the preclinical phase of RA. A comprehensive analysis of miRNAs revealed the dysregulation of miR-451 in peripheral blood mononuclear cells (PBMC) and plasma from RA-risk individuals. Higher miR-451 expression in PBMC from RA-risk individuals was further validated. Notably, miR-451 was previously shown to regulate CXCL16, a protein involved in RA pathogenesis. The expression of miR-451 in PBMC positively correlated with the CXCL16 mRNA, which could be secondary to the inflammation-induced expression of miR-451. Transfection of monocytes with pre-miR-451 in vitro resulted in the downregulation of CXCL16. Moreover, flow cytometry revealed a lower count of CXCL16-positive monocytes in RA-risk individuals. We propose that the constitutive or inflammation-induced upregulation of miR-451 in PBMC downregulates the expression of CXCL16, reduces the inflammatory milieu and thereby strives to delay the shift from the preclinical phase to the clinical manifestation of RA. This hypothesis warrants further investigation.

Department of Rheumatology 1St Faculty of Medicine Charles University Prague 128 00 Czech Republic

Faculty of Science Charles University Prague 128 00 Czech Republic

Institute of Rheumatology Prague 128 50 Czech Republic

Zobrazit více v PubMed

Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–2749. doi: 10.1002/art.11223. PubMed DOI

Raza K, Klareskog L, Holers VM. Predicting and preventing the development of rheumatoid arthritis. Rheumatology (Oxford) 2016;55:1–3. doi: 10.1093/rheumatology/kev261. PubMed DOI PMC

Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581. doi: 10.1002/art.27584. PubMed DOI

Ten Brinck RM, et al. The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. Rheumatology (Oxford) 2017;56:2145–2153. doi: 10.1093/rheumatology/kex340. PubMed DOI PMC

Gerlag DM, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: The PRAIRI study. Ann. Rheum. Dis. 2019;78:179–185. doi: 10.1136/annrheumdis-2017-212763. PubMed DOI PMC

Filkova M, Jungel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: Potential role in diagnosis and therapy. BioDrugs. 2012;26:131–141. doi: 10.2165/11631480-000000000-00000. PubMed DOI

Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008;105:10513–10518. doi: 10.1073/pnas.0804549105. PubMed DOI PMC

Hunter MP, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008;3:e3694. doi: 10.1371/journal.pone.0003694. PubMed DOI PMC

Arroyo JD, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011;108:5003–5008. doi: 10.1073/pnas.1019055108. PubMed DOI PMC

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011;13:423–433. doi: 10.1038/ncb2210. PubMed DOI PMC

Zhang F, Huang W, Sheng M, Liu T. MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients. Tumour Biol. 2015;36:2041–2048. doi: 10.1007/s13277-014-2811-2. PubMed DOI

Li CH, et al. CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway. Inflamm. Res. 2016;65:193–202. doi: 10.1007/s00011-015-0905-y. PubMed DOI

Abel S, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 2004;172:6362–6372. doi: 10.4049/jimmunol.172.10.6362. PubMed DOI

Ouboussad L, et al. Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. Arthritis Res. Ther. 2017;19:288. doi: 10.1186/s13075-017-1492-9. PubMed DOI PMC

Wang H, Peng W, Ouyang X, Li W, Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl. Res. 2012;160:198–206. doi: 10.1016/j.trsl.2012.04.002. PubMed DOI

Smigielska-Czepiel K, et al. Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes Immun. 2014;15:115–125. doi: 10.1038/gene.2013.69. PubMed DOI PMC

Wigerblad G, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann. Rheum. Dis. 2016;75:730–738. doi: 10.1136/annrheumdis-2015-208094. PubMed DOI PMC

Sun X, Zhang H. miR-451 elevation relieves inflammatory pain by suppressing microglial activation-evoked inflammatory response via targeting TLR4. Cell Tissue Res. 2018;374:487–495. doi: 10.1007/s00441-018-2898-7. PubMed DOI

Rosenberger CM, et al. miR-451 regulates dendritic cell cytokine responses to influenza infection. J. Immunol. 2012;189:5965–5975. doi: 10.4049/jimmunol.1201437. PubMed DOI PMC

Wang ZC, et al. MiR-451 inhibits synovial fibroblasts proliferation and inflammatory cytokines secretion in rheumatoid arthritis through mediating p38MAPK signaling pathway. Int. J. Clin. Exp. Pathol. 2015;8:14562–14567. PubMed PMC

Murata K, et al. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol. 2014;66:549–559. doi: 10.1002/art.38269. PubMed DOI

Iwakawa HO, Tomari Y. The functions of MicroRNAs: mRNA decay and translational repression. Trends Cell Biol. 2015;25:651–665. doi: 10.1016/j.tcb.2015.07.011. PubMed DOI

van Lieshout AW, et al. Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann. Rheum. Dis. 2009;68:1036–1043. doi: 10.1136/ard.2007.086611. PubMed DOI

Nanki T, et al. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005;52:3004–3014. doi: 10.1002/art.21301. PubMed DOI

Ruth JH, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 2006;54:765–778. doi: 10.1002/art.21662. PubMed DOI PMC

van der Voort R, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 2005;52:1381–1391. doi: 10.1002/art.21004. PubMed DOI

Wilbanks A, et al. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J. Immunol. 2001;166:5145–5154. doi: 10.4049/jimmunol.166.8.5145. PubMed DOI

van Lieshout AWT, et al. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Ann. Rheum. Dis. 2007;66:1334–1338. doi: 10.1136/ard.2006.066084. PubMed DOI PMC

Zhang L, et al. Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle, promoting muscle regeneration. Am. J. Pathol. 2009;175:2518–2527. doi: 10.2353/ajpath.2009.090275. PubMed DOI PMC

Isozaki T, Rabquer BJ, Ruth JH, Haines GK, 3rd, Koch AE. ADAM-10 is overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis. Arthritis Rheum. 2013;65:98–108. doi: 10.1002/art.37755. PubMed DOI

van de Sande MG, et al. Different stages of rheumatoid arthritis: Features of the synovium in the preclinical phase. Ann. Rheum. Dis. 2011;70:772–777. doi: 10.1136/ard.2010.139527. PubMed DOI

Filkova M, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2014;73:1898–1904. doi: 10.1136/annrheumdis-2012-202815. PubMed DOI PMC

Prajzlerova K, Grobelna K, Pavelka K, Senolt L, Filkova M. An update on biomarkers in axial spondyloarthritis. Autoimmun. Rev. 2016;15:501–509. doi: 10.1016/j.autrev.2016.02.002. PubMed DOI